Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Arbutus Biopharma Corporation

Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
From Arbutus Biopharma Corporation
Via Globe NewsWire
Tickers ABUS
Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research
From Arbutus Biopharma Corporation
Via Globe NewsWire
Tickers ABUS
Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update
From Arbutus Biopharma Corporation
Via Globe NewsWire
Tickers ABUS
Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via Globe NewsWire
Tickers ABUS
Arbutus to Participate in Three Upcoming Investor Conferences
From Arbutus Biopharma Corporation
Via Globe NewsWire
Tickers ABUS
Arbutus Announces Resignation of Board Member
From Arbutus Biopharma Corporation
Via Globe NewsWire
Tickers ABUS
Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
From Arbutus Biopharma Corporation
Via Globe NewsWire
Tickers ABUS
Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection
From Arbutus Biopharma Corporation
Via Globe NewsWire
Tickers ABUS
Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via Globe NewsWire
Tickers ABUS
Arbutus to Present at Jefferies London Healthcare Conference
From Arbutus Biopharma Corporation
Via Globe NewsWire
Tickers ABUS
Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®
From Arbutus Biopharma Corporation
Via Globe NewsWire
Tickers ABUS
Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022
From Arbutus Biopharma Corporation
Via Globe NewsWire
Tickers ABUS
Arbutus to Report Third Quarter 2022 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via Globe NewsWire
Tickers ABUS
Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End
From Arbutus Biopharma Corporation
Via Globe NewsWire
Tickers ABUS
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.